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Abstract
Background: Definitive chemoradiotherapy is standard of care in locally advanced cervical cancer (LACC). Both toxicity
and local relapse remain major concerns in this treatment. We hypothesize that a magnetic resonance imaging (MRI)
based redefining of the radiotherapeutic target volume will lead to a reduction of acute and late toxicity. In our center,
chemoradiotherapy followed by hysterectomy was implemented successfully in the past. This enables us to assess the
safety of reducing the target volume but also to explore the biological effects of chemoradiation on the resected
hysterectomy specimen.
Methods: The EXIT-trial is a phase II, single arm study aimed at LACC patients. This study evaluates whether a MRI-based
exclusion of the non-tumor-bearing parts of the uterus out of the target volume results in absence of tumor in the non-
high doses irradiated part of the uterus in the hysterectomy specimen. Secondary endpoints include a dosimetric
comparison of dose on normal tissue when comparing study treatment plans compared to treatment of the whole uterus
at high doses; acute and chronic toxicity, overall survival, local relapse- and progression-free survival. In the translational
part of the study, we will evaluate the hypothesis that the baseline apparent diffusion coefficient (ADC) values of diffusion
weighted MRI and its evolution 2 weeks after start of CRT, for the whole tumor as well as for intra-tumoral regions, is
prognostic for residual tumor on the hysterectomy specimen.
Discussion: Although MRI is already used to guide target delineation in brachytherapy, the EXIT-trial is the first to use this
information to guide target delineation in external beam radiotherapy. Early therapy resistance prediction using DW-MRI
opens a window for early treatment adaptation or further dose-escalation on tumors/intratumoral regions at risk for
treatment failure.
Trial registration: Belgian Registration: B670201526181 (prospectively registered, 26/11/2015); ClinicalTrials.gov Identifier:
NCT03542942 (retrospectively registered, 17/5/2018).
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Background
Definitive chemoradiotherapy (CRT) is considered standard
of care in Locally Advanced (FIGO 1B2-IVA) Cervical Can-
cer (LACC). Definitive CRT is a 2-steps process consisting
of external beam radiotherapy (EBRT) ± chemotherapy (If
possible cisplatin) and a brachytherapeutic (BT) boost. Even
with the use of image-guided dose-intensified BT, local re-
lapse arising from CRT-resistant foci is high (3y-local pelvic
control rates of 73% up to 96%, depending on stage and
treating center) and remains a major cause of treatment
failure [1–3]. In exchange for an improved overall survival
(OS), adding chemotherapy to conventional EBRT has
doubled the risk of severe acute hematological and
gastro-intestinal toxicity and tripled platelet toxicity [4].
Triggered off by both the high local recurrence and the
toxicity rates we challenged the gold standard by introdu-
cing intensity-modulated arc therapy (IMAT) followed by
C1 radical hysterectomy (HRT) [5]. This HRT allows re-
moving CRT-resistant tumor foci [6, 7]. IMAT reduces
the dose to the surrounding normal organs (organs at risk
=OARs) while enabling the delivery of a simultaneously
integrated boost (SIB) to the primary tumor and/or en-
larged lymph nodes [8]. Such a SIB, which replaces the BT
boost, maximally exploits the positive relationship be-
tween higher doses, shorter overall treatment time and
tumor control [9]. The combination of IMAT and chemo-
therapy (if possible, cisplatin is called IMAT-C. We re-
ported previously that using IMAT-C safely allows for a
post-IMAT-C HRT. Local control and survival rates were
promising and both IMAT-C and surgical related toxicity
rates were low [6, 7]. Further research aiming at decreas-
ing toxicity and increasing disease control is needed.
We hypothesize that redefinition of the target volume
(TV) will lead to a further reduction of acute and late tox-
icity. Apart from treating the tumor (“gross tumor vol-
ume” or GTV) to the highest dose, international
guidelines advise to treat organs having a risk of micro-
scopic disease (“clinical target volume” or CTV) also to
the same (or high) dose. In case of LACC, the uterus is
one of these organs. Influenced by bladder and/or rectal
filling and tumor shrinkage, the uterus can tilt from ante-
flexed to retroflexed position. Angle rotations of 30° and
more are noted in up to 1/5 patients [10]. This movement
of the uterus and consequently the CTV remains a major
problem. Concerns about these CTV movements (with
the uterine fundus being the main contributor) have lead
to the use of generous margins (up to 4 cm around the
uterine fundus) to create the planning target volume or
PTV [11]. In this way adequate coverage of the CTV at all
time is ensured. Consequently, the volume of irradiated
normal tissue is large and the risk of toxicity increases.
However, there is no unequivocal evidence supporting the
dogma that the whole uterus should be included in the
CTV [12]. This “inclusion-dogma” goes back to the pre-
magnetic resonance imaging (MRI) era where one could
not differentiate the tumor from the uterus. Nowadays,
MRI allows discrimination of the tumor with a high level
of accuracy [13, 14]. Therefore, we hypothesize that ex-
cluding the non-tumor-bearing parts from the CTV, based
on the MRI, leads to significant reductions in normal tis-
sue irradiated (OARs) with tighter PTV margins [15] and
reduced toxicity. Above that, HRT post-CRT gives us the
unique opportunity to explore the biological effects of
IMAT-C at the resected HRT specimen.
Methods/design
Study design
The EXIT-trial is a phase II, single arm study. The study
was initiated by the Department of Radiation Oncology
in collaboration with the Departments of Radiology,
Pathology, Medical Oncology and Gynaecologic Oncol-
ogy (Ghent University Hospital, Ghent Belgium).
Study objectives and endpoints
The objective of this study is to assess the safety of ex-
cluding the non-involved uterus from the TV in the de-
finitive CRT treatment of LACC. The primary endpoint
is absence of tumor in the non-involved (as determined
on the pre-treatment MRI) and non-high doses irradi-
ated part of the uterus in the hysterectomy specimen
after CRT. Secondary endpoints include a dosimetric
comparison of dose on the OARs when comparing study
treatment plans to treatment of the whole uterus at high
doses; acute and chronic toxicity, OS, local relapse free
and progression free survival (PFS). A translational part
of the study is discussed below.
Inclusion/exclusion criteria
Eligible patients suffer from biopsy proven carcinoma of
the uterine cervix. Following inclusion criteria should be
met: locally advanced disease (FIGO IB2 or > FIGO IIB
or node positive) proven by clinical examination,
18-fluorodeoxyglucose positron emission tomography
scan (18FDG PET-CT) and MRI; no more than 2 distant
metastases (other than para-aortic or inguinal lymph
nodes); WHO 0–2; adequate kidney function for cis-
platin, in case of inadequate kidney function cisplatin
can be replaced by 5-FU or radiotherapy can be the sole
therapeutic regimen; not pregnant or breastfeeding; ab-
sence of any psychological, familial, sociological or geo-
graphical condition potentially hampering compliance
with the study protocol and follow-up schedule; willing
and able to sign a written informed consent. Patients un-
able to undergo MRI for any reason are excluded.
Interventions
Figure 1 illustrates the patient-flowchart and all trial-related
procedures.
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Radiation treatment planning
After imaging in treatment position (standard procedure
or state of the art: 18FDG PET-CT and MRI as described
in Fig. 1) [7, 8] and fusion with the RT-planning-CT,
TVs and OARs will be delineated. Planning CT (p-CT)
was taken on a Toshiba 16 slice CT scanner, in supine
position, using intravenous and bowel contrast. Patients
were scanned with a comfortable filled bladder. Delin-
eated OARs include small intestine, rectum, sigmoid
colon, bladder and bone marrow. Per patient 2 sets of
PTV (see Fig. 2) will be generated, in which the PTV of
the lymph nodes (lnn), (=PTV_lnn) is identical:
PTV: PTV_prim + PTV_lnn (state-of-the-art, as
performed out of this trial)
PTV_prim is created by an anisotropic expansion around
the CTV of the primary (prim) tumor (= CTV_prim) of
10 mm antero-posterior (AP); 5 mm left-right (LR) and
5 mm supero-inferior (SI). CTV_prim consists of the pri-
mary tumor delineated using T2 weighted MRI images
(GTV_prim) + whole uterus + non-affected parts of the
cervix and parametria + upper vaginal 1/3 to ½ (minimal
vaginal margin of 2 cm to the GTV_prim).
PTV_lnn is created using an isotropic margin of
5 mm around the CTV_lnn (CTV of the lnn) which
consists of the union of following regions: common-, ex-
ternal- and internal iliac lnn, obturator and presacral
region and para-aortic lnn if any pelvic lnn are affected.
A lymph node is considered affected when.
PTV_EXIT: PTV_prim_EXIT + PTV_Lnn
PTV_prim_EXIT is created using an anisotropic margin
around the CTV_prim_EXIT of 7 mm AP; 5 mm LR and
5 mm SI. CTV_prim_EXIT consists of the GTV_prim +
uterus within 1,2 cm around GTV_prim [16] +
non-affected parts of the cervix and parametria + upper va-
ginal 1/3 to ½ (minimal margin of 2 cm around the
GTV_prim). The PTV_lnn is identical as discussed above.
A treatment plan is made for both TVs using the Ray-
search planning system (RaySearch Laboratories, Stockholm,
Sweden) using identical prescription and constraints as in
our previously published work [7, 8]. In short, a minimal
dose (D98) of 45 Gy in 25 fractions is prescribed to the PTV
and PTV_EXIT. A minimal dose (D98) of 62Gy is pre-
scribed to the GTV_prim, a minimal dose of 60Gy is pre-
scribed to any affected lnn.
Treatment
The patient will be treated with the “PTV_EXIT”
treatment plan, in 25 fractions. All treatments will be
performed on an Elekta (Crawley, UK) Synergy linac
with gantry mounted Cone Beam CT option. Daily
Couch setup correction will be done after
pre-treatment CBCT imaging consisting of M20 Field
Fig. 1 Workflow per patient and situation of the different time-points for each study. DW-MRI: diffusion-weighted MRI; PTV_EXIT: planning target
volume as defined within the EXIT-trial; MRI HRT: Magnetic resonance imaging of the HRT specimen; FDG-PET: 18-fluorodeoxyglucose PET scan;
PTV: planning target volume; MRI: magnetic resonance imaging. C: weekly chemotherapy; RT: radiotherapy; D98: dose received in 98% of the
volume. *: Imaging which requires extra effort of the patient; **: only if node-positive at diagnosis
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of View (i.e. 27,7 cm in SI direction), with bowtie fil-
ter, 120KV, 40 mA and 40 ms per frame, and 0,5 rpm
gantry rotation speed. If necessary, adaptive treatment
planning or plan-of-the-day is allowed.
Cisplatin 40 mg/m2 will be administered weekly during
radiotherapy. In case of inadequate kidney function or
other contra-indications, 5-FU or no chemotherapy is
also allowed. Within 6 to 8 weeks after ending chemora-
diation, a radical hysterectomy (Cibula classification: C1)
will be performed [5].
Imaging during and after treatment
All patients will undergo MRI at fixed time points
(see Fig. 1 and Table 1). The MRI before, during and
2–3 weeks after CRT are considered routine standard
procedures at our hospital. The MRI at the end of
the treatment and within 1 week before HRT is sup-
plemental for the study. The first is considered essen-
tial for adequate regression pattern analysis. The last
MRI allows constructing a mold (e.g. 3D printing,
widely available), which will act as a 3-dimentional
rendering of the pre-HRT “uterine bed” and its slope.
This allows mimicking the same position and angle
rotation of the uterus as within the patient, which is
necessary to allow for an adequate regression pattern
analysis. After HRT, the HRT specimen itself will be
scanned in the same position as within the patient,
using the 3D-mold. The use of the 3D-mold will
allow MRI-pathology comparison.
The process to create the 3D mold starts with the
conversion of a set of 2D contour slices delineated
on the last MRI to a 3D volume using an in-house
implemented marching cubes algorithm. The 3D vol-
ume is imported into Blender, an open-source 3D
graphics software package. Around the imported vol-
ume, a box is generated using Python scripts and
the uterus volume is subtracted from this box. The
box is cutout further to support the lower half of
the uterus specimen. On the side of the box, knobs
are added to enable fixation of the tissue to the
mold (Fig. 3).
Fig. 2 delineation of treatment volumes following state-of-the-art (a en b) en EXIT-trial (a en c). a delineation of elective lymph node areas are
state-of-the-art and identical in standard treatment & the EXIT_trial. Clinical target volume (CTV) of the lymph nodes (lnn) = CTV_Lnn (yellow) =
elective lnn areas (common, external and internal lnn, obturator and presacral region; inclusion of para-aortic lnn if any pelvic lnn are affected).
Planning target volume (PTV) of the lnn (PTV_Lnn; blue) is created using an isotropic margin of 5 mm around the CTV_Lnn. b GTV of the primary
tumor (GTV_prim = red): primary tumor delineated using T2 weighted MRI images (state of the art). CTV of the primary tumor (CTV_prim = blue):
includes GTV_prim, whole uterus, non-affected parts of the cervix and parametria, upper vaginal 1/3 to ½ (minimal vaginal margin of 2 cm to the
GTV_prim). PTV of the primary tumor (PTV_prim = purple): margin around the CTV_prim of 10 mm antero-posterior (AP); 5 mm left-right (LR) and
5 mm supero-inferior (SI)
Table 1 MRI scan sequences
Timing MRI Scan Sequence & used MRI device
Standard MRI before, during
and 2–3 weeks after CRT
5 mm sagittal T2 Haste, 5 mm sagittal
T2 TSE, 4 mm axial T2 TSE, 5 mm axial
T1 GE, 4 mm axial DWI (b-values 0, 250,
500 and 1000 with calculated b 1400)
at 1.5 Tesla MRI scanner (Siemens Aera,
Erlangen, Germany)
Supplemental MRI at the end
of treatment and pre-HRT
5 mm sagittal T2 Haste, 5 mm sagittal
T2 TSE, 4 mm axial T2 TSE, 5 mm axial
T1 GE, 4 mm axial DWI (b-values 50,
400 and 800 with calculated b 1400)
at 3.0 Tesla MRI scanner (Siemens Trio
or Prisma Fit, Erlangen, Germany)
Hysterectomyspecimen 1 mm coronal T2 Space with 1 mm
sagittal and axial reconstructions, 4 mm
axial DW (b-values 50, 250,500,750,1000
with calculated b 1400)
at 3.0 Tesla MRI scanner (Siemens Trio
or Prisma Fit, Erlangen, Germany)
MRI magnetic resonance imaging, mm millimeter, TSE Turbo Spin Echo, GE
Gradient Echo, DWI diffusion weighted imaging
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Clinicopathological examination
Upon receival, the fresh specimen will be removed from
the 3D-mold and will be oriented, measured and
weighed. The parametrial tissues, the soft tissue mar-
gins of the cervical canal and the vaginal cuff margin
will be inked blue and green, signifying the left and
right side, respectively. Parametria will be removed and
entirely submitted for histological examination. Next, a
probe will be inserted in the endocervical canal and the
uterine cavity. The uterus and cervix will be bisected
into posterior and anterior halves, to allow sufficient
tissue fixation. These halves will be pinned on plastic to
avoid curling of the tissue. The specimen will be
inspected and described. Any macroscopically visible
tumor will be measured and, if larger than 10 mm, a
tissue sample of about 5 × 3 × 3 mm will be snap-frozen
to allow future molecular studies. The bisected speci-
men will then be fixed in formalin for 24 h. After fix-
ation, the vaginal cuff and the cervix will be
transversally amputated and will be serially sectioned.
These perpendicular clockwise sections will allow the
assessment of the relationship of the tumor to the mar-
gin. Twelve, 3, 6 and 9 o’clock correspond with the an-
terior, left, posterior and right side of the cervix,
respectively. Transverse sections of the endocervical
canal and isthmus will be submitted for histological
examination as well. The uterine corpus, fallopian tubes
and ovaries will be macroscopically examined for ab-
normalities, and representative tissue samples will be
submitted for histological examination. If initial
hematoxylin and eosin (HE) stained tissue sections do
not reveal any tumor rest in the cervix, multiple deeper
sections will be performed. Additional immunohisto-
chemistry for p40 and Cytokeratin5 will be performed
to illustrate any residual isolated tumor cells when HE
slides are deemed unclear. Any residual tumor, its
localization and its relation to the surgical resection
margins will be described in the report.
Radiological-histological correlation
Transfer of the clinicopathological information to the
post-HRT MRI will be done in cooperation with the
pathologist and radiologist. In-house developed software
in RayStation 6.0 allows correlation of tumor location in
between the planning CT, the MRI scanned specimen
and the HRT pathology result. Initially a gray based, re-
gion of interest constraint rigid fusion is done between
the specimen and the planning CT, followed by a
non-rigid hybrid deformable registration. Fusion of these
MRIs with the planning-CT and treatment-plan will
allow to allocate the remaining tumor in or out of the
high-dose irradiated field.
Fig. 3 3D-mold. Example of a 3D-mold model created in Blender. The uterus, mold and knobs are depicted respectively in white, blue and green.
The mold supports the uterus specimen, while the tissue is fixated to the knobs during sugery
Vandecasteele et al. BMC Cancer  (2018) 18:898 Page 5 of 10
Follow-up
Acute toxicity will be scored conform previous studies
(weekly during therapy, 10 days and 1 and 3 months after
completing CRT) using a combination of RTOG supple-
mented with own grading for those toxicities not com-
prised in the RTOG scoring and CTCAE for hematologic
toxicity [7, 17]. This will allow for matched-case compari-
son for acute toxicity with patients treated in previous
studies [7, 17]. Chronic radiation toxicity (toxicity occur-
ring > 3 months after completing CRT or acute toxicity
lasting longer than 3 months) will be assessed at every
follow-up visit conform previous studies [7, 17]. Again,
this will allow for matched-case comparison for toxicity
with patients treated in previous studies.
Local (LC), regional (RC) and distant control is de-
fined as absence of disease at the primary tumor bed,
the regional lymph nodes and distant sites respectively.
Time to local relapse, regional relapse and distant re-
lapse were defined as the time elapsed between biopsy
and the first event (local, regional or distant relapse) or
the last follow-up. PFS and OS were defined as the time
elapsed between biopsy and any progression, death or
the last follow-up.
Additional and translational research
Planning study
Per patient, two different treatment plans (prescribed on
PTV and PTV_EXIT as described above) will be gener-
ated. The OARs are the same for both plans and include
small intestine, rectum, sigmoid colon, bladder and bone
marrow. Prescription details can be found in our previ-
ous work [7, 8]. Dose Volume Histograms (DVHs) for all
OARs will be calculated and compared between the two
treatment plans. Per OAR, fixed dose-volume points of
clinical relevance (e.g. volume of small bowel receiving
≥45 Gy, as used in previous research [8]) will be used
for statistical comparison.
Correlation of high-risk regions on IMaging (DW-MRI) with
pathology and regression pattern analysis (CRIMP)
The same patients who are the subjects of the clinical
study will also be the subjects of the CRIMP study. The
MRI at fixed time points (see Fig. 1) will be supplemented
with diffusion weighing (DW). DW provides information
about the amount of random movement of water mole-
cules in a tissue. In healthy tissues the water molecules
move relatively unhindered but in cancer the motion is
strongly inhibited. This is depicted on DW as a high signal
intensity area on high-b-value images with a correspond-
ing low apparent diffusion coefficient (ADC) [18]. The ul-
timate aim of the CRIMP study is the correlation of
tumoral ADC-values of the different DW-MRI with the
pathology in order to predict therapy resistance or re-
sponse to CRT at an early stage or even before start. The
response on treatment assessed with pathology will be di-
vided into 3 categories: A) no residual tumor or micro-
scopic tumor rest consisting of fibrosis containing foci of
neoplastic cells (the presence of isolated tumor cells/nests
will not be considered as residual disease), B) macroscopic
(> 7 mm) tumor rest revealing obvious tumor mass but
showing CRT response and C) neoplastic tissue without
any effect of radiation or regression. A high Apparent Dif-
fusion Coefficient (ADC)mean and limited increase (< 15%)
in ADCmean value 2 weeks after start of CRT corresponds
with impaired response and survival [19, 20]. We
hypothesize this will also correlate with residual tumor
(isolated tumor cells excluded) at the HRT specimen. Both
ADCmean and median increase in ADCmean will be corre-
lated with the same pathology categories as mentioned
here above.
Statistical considerations
For the EXIT-trial; 21 patients are required to achieve a
confidence interval with a half width of 11%, considering
a negative predictive value of 98% for MRI [13] to pre-
dict absence of tumor (Wilson Score Confidence Inter-
val for a Binomial Proportion). These patients will also
be used for the observational CRIMP trial. For the plan
comparison, statistics will be done using a paired T-test.
All statistical analysis will be performed using SPSS.
Ethical considerations
The study will be conducted in agreement with the Dec-
laration of Helsinki. The protocol was approved by the
Ethical Committee of Ghent University Hospital. All data
collected for the purpose of research will be kept confi-
dential. The patient’s identity will never be disclosed.
Discussion
Definitive chemoradiation is considered standard of care for
LACC, wherein radiotherapy plays a crucial role. Unfortu-
nately, toxicities caused by radiotherapy are frequent. Add-
ing chemotherapy to conventional EBRT has even doubled
the risk of severe acute hematological and gastro-intestinal
toxicity and tripled platelet toxicity, in exchange for an im-
proved OS [4]. Efforts to reduce this toxicity have only been
successful in the last decades. As the understanding of
radiation and radiation techniques improved, intensity
modulated RT (IMRT) and arc techniques have become
more prevalent and the standard-of-care to deliver EBRT in
cervical cancer based on reduced gastro-intestinal (GI),
genito-urinary (GU) and hematological toxicity [7, 17, 21–
24]. Preliminary results from the only randomized trial
comparing IMRT and conventional RT confirm a significant
reduction in GI and GU toxicity “(https://clinicaltrials.gov/
ct2/results?pg=1&load=cart&id=NCT01672892)”. The pub-
lication of the GEC-ESTRO recommendations for image-
guided adaptive brachytherapy (IGABT) one decade ago
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was a significant step forward for the brachytherapeutic
treatment of LACC. In the RetroEMBRACE study, the im-
proved OS of 10% compared to historical series was ac-
companied with a limited severe (G3 or more) morbidity
(3–6% per organ) [3, 25]. This is in agreement with other
mono-institutional series, as is the observation that mild
morbidity remains frequent with major impact on quality
of life [3]. Hence, treatment related morbidity remains a
major challenge. As the evolution in treatment techniques
is doomed to reach its limits, other toxicity reducing ef-
forts should be explored. The exquisite soft-tissue contrast
of MRI has meant that the technique is having an increas-
ing role in initial local staging, treatment planning (EBRT
and IGABT) and for treatment monitoring of patients
with advanced cervical cancer undergoing CRT. Despite
the fact that MRI has been the imaging modality of choice
for RT delineation [26], its ability to predict absence of
tumor in the uterus has never been used to reduce treat-
ment fields. Above that, there is no unequivocal evidence
supporting the dogma that the whole uterus should be in-
cluded in the CTV [26]. Despite the aforementioned rea-
soning, it remains to be proven that omitting unaffected
parts of the uterus is safe, leads to lower dose to OARs
(Fig. 4) reflecting in reduced toxicity.
At this moment, MRI is widely used for initial local
staging and target/OAR delineation and also increasingly
used for monitoring treatment response after CRT.
However, the accuracy of conventional MRI techniques
Fig. 4 Dose Volume Histograms with and without the entire uterus included in the planning target volume. Dose Volume Histograms (DVHs) of
2 patients treated with a partial (yellow) or entire uterus (red) included in the planning target volume (PTV). a and c red contour = entire uterus
included in the PTV; yellow contour = only the parts of the uterus closer than two cm of the gross tumor volume (GTV = red flooded contour) are
included in the PTV. c and d DVHs of patient a and c respectively; the red DVHs correspond with the red contour (whole uterus); the yellow
DVHs correspond with the yellow contour (selected parts of the uterus included in the CTV). The tail towards 62Gy in the DVH of the PTV
corresponds with the SIB given to the GTV. In the first patient (a) the uterus lies in anteflexed position causing high doses to the bladder when
irradiated entirely. A small reduction of PTV by reducing the amount of uterus included in the PTV causes a huge reduction in dose delivered to
the bladder (b). A reduction of the PTV in case of a normal positioned uterus causes mainly a reduction in the irradiated volume of small bowel
(d). Due to the large amounts of small bowel delineated, the reduction in terms of percentage seems small. However, in this case the amount of
small bowel receiving 45Gy is reduced with 8%, which corresponds with 59 cc
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only (T2 sequences) is less than DW-imaging for
monitoring treatment response [27, 28]. A clinical and
iconographical complete response after CRT predicts a bet-
ter outcome, whereas macroscopic residual disease at the
HRT specimen is an adverse prognostic factor for survival
[29]. Residual disease reflects radio-resistant tumor clones,
which are more aggressive and eventually lead to
cancer-related mortality. Overcoming this radioresistance
with a more aggressive treatment and/or higher doses might
improve outcome. However, not all tumors as well as not all
intra-tumoral sub-regions require a more aggressive ap-
proach. Biological heterogeneity within a tumor is a
well-recognized phenomenon, which critically influences
treatment outcome [30]. Local failure is likely more
adversely influenced by those at-risk sub-regions (tumor
voxels) within the heterogeneous tumor, which possess
unfavorable biological properties. Early assessment of tumor
response and at-risk sub-regions would permit modification
of strategy during therapy by escalating the dose on
non-responsive regions within the tumor or de-escalating
dose in responsive regions. In cervical cancer, several studies
have shown the utility of DW-MRI in the prediction or
monitoring of response to CRT or in the prediction of
recurrent disease. DW-MRI can yield quantitative informa-
tion by means of serial ADC-measurements [31].
Treatment-induced cell damage precedes morphological
changes and is associated with increased ADC-values, which
are reliable in predicting treatment response [27, 32].
Already 2 weeks after start of CRT, ADCmean and the change
in ADCmean from the baseline correlate with the final MRI
response [19, 33, 34] and with survival [20]. Liu et al. [33]
found that also baseline ADC values are significantly lower
for the patients achieving a complete radiological response
than those achieving a partial response. Tumors with high
baseline ADC are likely to be more necrotic than those with
low baseline ADC, which in turn predicts poor outcomes re-
lated to hypoxia-mediated radio-resistance [35]. However,
few tumors do not respond favorably to CRT despite having
lower pretreatment ADC values [36]. This may be due to
the fact that necrosis within a tumor is not always associated
with a high ADC. In theory, coagulative necrosis without
tumor cell liquefaction may not increase the ADC [36]. It is
therefore essential to combine pretreatment ADC value with
the change in this value after 2 weeks of treatment for re-
sponse prediction. To date, studies have focused on
ADCmean, based on a region of interest (ROI) defined as the
whole tumor or on 1 slice of the whole tumor [37]. Accord-
ing to the above-mentioned findings, radioresistant regions
within the tumor will have higher baseline ADC values [33]
and less change in ADC at 2 weeks [19, 33, 34, 36]. We
hypothesize that baseline ADC and its evolution 2 weeks
[36] after start of CRT will correlate with tumor rest in the
hysterectomy specimen and that future dose escalation to
those “at-risk” regions within the GTV could reduce the
amount of residual macroscopic disease. In this way,
DW-MRI could be used for assessing early treatment re-
sponse and functional tumor heterogeneity for a personal-
ized cancer RT strategy.
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LR: Left-Right; mA: milliAmpere; MRI: Magnetic Resonance Imaging;
ms: milliseconds; OAR(s): Organ(s) at Risk; OS: Overall Survival; 18 FDG PET-
CT: 18-fluorodeoxyglucose PET scan; PFS: Progression Free Survival;
Prim: Primary tumor; PTV: Planning Target Volume; RC: Regional Control;
RT: Radiotherapy; RTOG: Radiation Therapy Oncology Group; SI: Supero-inferior;
SIB: Simultaneously Integrated Boost; TSE: Turbo Spin Echo; TV: Target Volume
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